TNF and atherosclerosis: While targeting this inflammatory cytokine through the genetic disruption of TNFα decreases atherosclerosis in mice, the pharmacological inhibition of TNFα through the administration of anti-TNFα monoclonal antibody in Ldlr-/- mice increases the atherosclerotic plaque burden [129].